The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).
复制标题
DOI：
10.1186/s40425-018-0382-2
复制
发表时间：
2018-07-17
影响因子：
10.9
通讯作者：
Herbst RS
中科院分区：
文献类型：
--
作者：
Brahmer JR;Govindan R;Anders RA;Antonia SJ;Sagorsky S;Davies MJ;Dubinett SM;Ferris A;Gandhi L;Garon EB;Hellmann MD;Hirsch FR;Malik S;Neal JW;Papadimitrakopoulou VA;Rimm DL;Schwartz LH;Sepesi B;Yeap BY;Rizvi NA;Herbst RS
肺癌是全球癌症相关死亡的主要原因，其中非小细胞肺癌（NSCLC）占所有病例的85%以上。直到最近，化疗-以一些益处为特征，但只有罕见的持久反应-是肿瘤缺乏靶向突变的NSCLC患者的唯一治疗选择。相比之下，免疫检查点抑制剂已表现出明显持久的反应，代表了NSCLC患者新治疗方法的出现。三种免疫检查点抑制剂，pembrolizumab，nivolumab和atezolizumab，现已被批准用于选定的晚期NSCLC患者的一线和/或二线治疗，在III期NSCLC患者中也有很好的获益。此外，放化疗后的durvalumab已被批准用于局部晚期疾病患者。由于癌症免疫治疗的独特特征以及该领域的快速发展，需要对这些药物的使用进行临床指导，包括适当的患者选择，治疗顺序，反应监测，不良事件管理和生物标志物检测。癌症免疫治疗学会召集了一个专家工作队，负责就这些关键问题提出协商一致的建议。按照美国国家医学院概述的系统过程，使用文献检索和小组投票对每个建议的证据强度进行评级。该共识声明提供了基于证据的建议，以帮助临床医生将免疫检查点抑制剂纳入NSCLC患者的治疗计划。本指南将根据该领域的相关进展予以更新。本文的在线版本（10.1186/s40425-018-0382-2）包含补充材料，可供授权用户使用。
Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for over 85% of all cases. Until recently, chemotherapy – characterized by some benefit but only rare durable responses – was the only treatment option for patients with NSCLC whose tumors lacked targetable mutations. By contrast, immune checkpoint inhibitors have demonstrated distinctly durable responses and represent the advent of a new treatment approach for patients with NSCLC. Three immune checkpoint inhibitors, pembrolizumab, nivolumab and atezolizumab, are now approved for use in first- and/or second-line settings for selected patients with advanced NSCLC, with promising benefit also seen in patients with stage III NSCLC. Additionally, durvalumab following chemoradiation has been approved for use in patients with locally advanced disease. Due to the distinct features of cancer immunotherapy, and rapid progress in the field, clinical guidance is needed on the use of these agents, including appropriate patient selection, sequencing of therapies, response monitoring, adverse event management, and biomarker testing. The Society for Immunotherapy of Cancer (SITC) convened an expert Task Force charged with developing consensus recommendations on these key issues. Following a systematic process as outlined by the National Academy of Medicine, a literature search and panel voting were used to rate the strength of evidence for each recommendation. This consensus statement provides evidence-based recommendations to help clinicians integrate immune checkpoint inhibitors into the treatment plan for patients with NSCLC. This guidance will be updated following relevant advances in the field. The online version of this article (10.1186/s40425-018-0382-2) contains supplementary material, which is available to authorized users.
登录
查看更多内容
影响因子：
10.9
作者：
Boyiadzis M;Bishop MR;Abonour R;Anderson KC;Ansell SM;Avigan D;Barbarotta L;Barrett AJ;Van Besien K;Bergsagel PL;Borrello I;Brody J;Brufsky J;Cairo M;Chari A;Cohen A;Cortes J;Forman SJ;Friedberg JW;Fuchs EJ;Gore SD;Jagannath S;Kahl BS;Kline J;Kochenderfer JN;Kwak LW;Levy R;de Lima M;Litzow MR;Mahindra A;Miller J;Munshi NC;Orlowski RZ;Pagel JM;Porter DL;Russell SJ;Schwartz K;Shipp MA;Siegel D;Stone RM;Tallman MS;Timmerman JM;Van Rhee F;Waller EK;Welsh A;Werner M;Wiernik PH;Dhodapkar MV
通讯作者：
Dhodapkar MV
影响因子：
51.1
作者：
Ascierto, Paolo A.;Schadendorf, Dirk;Dummer, Reinhard
通讯作者：
Dummer, Reinhard
影响因子：
10.9
作者：
Grigg C;Rizvi NA
通讯作者：
Rizvi NA
影响因子：
3.3
作者：
Davies M
通讯作者：
Davies M
IV期或复发性非小细胞肺癌中的一线Nivolumab。
DOI：
10.1056/nejmoa1613493
发表时间：
2017-06-22
期刊：
The New England journal of medicine
影响因子：
--
作者：
Carbone DP;Reck M;Paz-Ares L;Creelan B;Horn L;Steins M;Felip E;van den Heuvel MM;Ciuleanu TE;Badin F;Ready N;Hiltermann TJN;Nair S;Juergens R;Peters S;Minenza E;Wrangle JM;Rodriguez-Abreu D;Borghaei H;Blumenschein GR Jr;Villaruz LC;Havel L;Krejci J;Corral Jaime J;Chang H;Geese WJ;Bhagavatheeswaran P;Chen AC;Socinski MA;CheckMate 026 Investigators
通讯作者：
CheckMate 026 Investigators